<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719225</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-056</org_study_id>
    <nct_id>NCT00719225</nct_id>
  </id_info>
  <brief_title>A Belatacept Compassionate Use Study for Patients With a Kidney Transplant</brief_title>
  <official_title>Belatacept for Renal Allograft Recipients: A Compassionate Use Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To make belatacept available for recipients of a renal allograft who are currently intolerant
      to or have contraindications to CNIs and/or m-TOR inhibitors and are either:

        -  unable to construct an adequate immunosuppression regimen due to non-renal toxicity /
           contraindication (and withdrawing the causative agent would lead to renal graft loss)

      OR

        -  at imminent risk of losing the allograft kidney due to nephrotoxicity and have no other
           options for renal replacement therapy
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Renal Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially</description>
    <other_name>LEA29Y</other_name>
    <other_name>BMS-224818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Please call 800-398-9157 for information on this study

        Inclusion Criteria:

          -  Men and women of age 18 years or older inclusive

          -  Recipient of a renal allograft for at least ≥ 2 months

          -  EBV positive

          -  Unable to tolerate a suitable immunosuppression regimen to prevent acute allograft
             rejection, due to:

          -  Extra-renal toxicity related to CNIs and/or m-TOR inhibitors that is refractory to
             medical management (eg, uncontrolled seizures)

          -  Contraindication to CNIs and/or m-TOR inhibitors

        OR

          -  At imminent risk of losing allograft kidney due to nephrotoxicity

          -  Renal failure: ≥ Stage 4 on KDOQI Scale (GFR 15 - 29 cc/min)

          -  And no other renal replacement therapy

          -  Subjects must be receiving the maintenance immunosuppressants MMF, MPA, or AZA

        Exclusion Criteria:

          -  Any significant infection, extra-renal solid organ (heart, liver, pancreas) or cell
             (islet, bone marrow, stem cell) transplants, with an unresolved episode of AR within
             the last 6 weeks

          -  EBV negative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office Of Dr. Allan Kirk</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Iberia</city>
        <state>Louisiana</state>
        <zip>70563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Abdominal Transplant</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Transplant Center Of The Lehigh Valley</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <last_update_submitted>July 13, 2011</last_update_submitted>
  <last_update_submitted_qc>July 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

